Displaying 2101 - 2120 of 4443
1604007 Informal Interpretation
1604005 Informal Interpretation
FTC and Justice Department Officials Meet with Officials of Chinese Antitrust Agencies
1604006 Informal Interpretation
1604004 Informal Interpretation
1604003 Informal Interpretation
FTC, DOJ Issue Joint Statement on Preserving Competition in the Defense Industry
FTC Workshop Will Examine Competition and Consumer Protection Issues in the Rooftop Solar Business
1604002 Informal Interpretation
FTC Approves Modification of Final Order Related to Pfizer’s 2009 Acquisition of Wyeth
FTC Chairwoman Releases 2015 Annual Highlights
Pfizer Inc., a corporation, and Wyeth, a corporation, In the Matter of
The Commission challenged Pfizer Inc.’s proposed $68 billion acquisition of Wyeth and required significant divestitures to preserve competition in multiple U.S. markets for animal pharmaceuticals and vaccines. The proposed consent order remedies the anticompetitive effects the Commission believes are likely to result from the transaction in numerous markets for animal vaccines and animal pharmaceutical products. After a thorough investigation, the Commission concluded that the transaction does not raise anticompetitive concerns in any human health product markets.
Prepared Statement of Maureen K. Ohlhausen: “Section 5 and ‘Unfair Methods of Competition’: Protecting Competition or Increasing Uncertainty?”
1604001 Informal Interpretation
FTC Approves Modified Final Order for Hikma Pharmaceuticals PLC
FTC Sues Endo Pharmaceuticals Inc. and Others for Illegally Blocking Lower-Cost Generic Versions of the Branded Drugs Opana ER and Lidoderm
Dissenting Statement of Commissioner Maureen K. Ohlhausen In the Matter of Endo Pharmaceuticals Inc.
Displaying 2101 - 2120 of 4443